Thirty out of these 36 HER2-positive patients were pN0 and in these patients the choice of administered chemotherapy was independent of other patient and tumour characteristics and based only on HER2-positivity, considered a poor prognostic factor [22-24], as well confirmed by recent studies [25-28]. The gene discussed is ERBB2; the disease is neoplasm.